These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 11302921)

  • 1. Atypical antipsychotics in the treatment of schizophrenia. Cost is a crucial issue.
    Duggins R; Rhinds D; Hall W
    BMJ; 2001 Apr; 322(7291):926; author reply 927-8. PubMed ID: 11302921
    [No Abstract]   [Full Text] [Related]  

  • 2. Atypical antipsychotics in the managed care era.
    Loebel AD; Botts SR; Feldman BI
    Am J Manag Care; 1998 Jan; 4 Suppl():S37-50; quiz S51-2. PubMed ID: 10181074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expensive but nevertheless cost effect? Pharmacoeconomics of atypical neuroleptics].
    Laux G; Günther W
    Pharm Unserer Zeit; 2002; 31(6):572-6. PubMed ID: 12481515
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
    Surguladze S; Patel A; Kerwin RW; Knapp M; Travis MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost analysis of the strategies in the treatment of schizophrenics: the place of sustained release injectable atypical antipsychotics].
    Gasquet I; Bouhassira M; Launois R
    Encephale; 2005; 31(4 Pt 1):517-8. PubMed ID: 16389719
    [No Abstract]   [Full Text] [Related]  

  • 7. [Consumption and cost of antipsychotic drugs].
    Pérez J; Marín N; Vallano A; Castells X; Capellà D
    Actas Esp Psiquiatr; 2005; 33(2):110-6. PubMed ID: 15768318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
    Obradovic M; Mrhar A; Kos M
    Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
    McCombs JS; Luo M; Johnstone BM; Shi L
    Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schizophrenia: multi-attribute utility theory approach to selection of atypical antipsychotics.
    Bettinger TL; Shuler G; Jones DR; Wilson JP
    Ann Pharmacother; 2007 Feb; 41(2):201-7. PubMed ID: 17311836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. False economy.
    Newstead C
    Nurs Times; 1997 Sep 24-30; 93(39):18. PubMed ID: 9355542
    [No Abstract]   [Full Text] [Related]  

  • 12. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
    Kilian R; Angermeyer MC
    Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to atypical antipsychotics: a public payor's perspective.
    Haveman JK
    Behav Healthc Tomorrow; 1998 Aug; 7(4):45-8. PubMed ID: 10182153
    [No Abstract]   [Full Text] [Related]  

  • 14. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.
    Gau SS; Chung CH; Gau CS
    J Clin Psychopharmacol; 2008 Jun; 28(3):271-8. PubMed ID: 18480683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.
    Ascher-Svanum H; Kennedy JS; Lee D; Haberman M
    Am J Manag Care; 2004 Jan; 10(1):20-4. PubMed ID: 14738183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comments on 'Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia'.
    Koh SS; Meyer JM
    Int J Clin Pract; 2008 Jul; 62(7):1119; author reply 1119-20. PubMed ID: 18564275
    [No Abstract]   [Full Text] [Related]  

  • 17. Economic grand rounds: systemwide costs associated with second-generation antipsychotics in the treatment of schizophrenia.
    Sernyak MJ; Rosenheck R
    Psychiatr Serv; 2004 Dec; 55(12):1361-2. PubMed ID: 15572563
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
    Keith S
    Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of atypical antipsychotics on outcomes of care in schizophrenia.
    Joyce AT; Harrison DJ; Loebel AD; Ollendorf DA
    Am J Manag Care; 2005 Sep; 11(8 Suppl):S254-61. PubMed ID: 16180964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.